Skip to main content
LAB logo

LAB · Standard Biotools Inc. · Executive Compensation

Track LAB — free
$0.63 +0.02 (+2.82%) At close · Nov 20 Q1 2025 earnings call transcript
Market Cap
$249.11M
Shares
394.79M
Volume · Nov 20 2.81M Avg daily vol (3M) 1.2M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Michael Egholm $8,823,502
Alex Kim $4,005,165
Sean Mackay $1,692,543
Fiscal 2024
Executive Total
Michael Egholm $8,337,044
Sean Mackay $3,177,155
Alex Kim $3,090,340
Fiscal 2023
Executive Total
Michael Egholm $1,931,088
Jeffrey G. Black $1,492,297
Alex Kim $909,788
Sean Mackay —
Fiscal 2022
Executive Total
Michael Egholm $15,895,848
Alex Kim $5,856,938
Stephen Christopher Linthwaite $1,638,601
Jeremy Davis $1,404,172
Jeffrey G. Black —
Sean Mackay —
Fiscal 2021
Executive Total
Stephen Christopher Linthwaite $3,311,662
Colin McCracken $1,386,353
Vikram Jog $1,105,664
Nicholas Khadder $920,559
Bradley Kreger $894,346
Fiscal 2020
Executive Total
Stephen Christopher Linthwaite $3,800,867
Colin McCracken $1,657,454
Vikram Jog $1,443,226
Bradley Kreger $1,385,499
Nicholas Khadder $1,050,529
Fiscal 2019
Executive Total
Stephen Christopher Linthwaite $3,713,055
Colin McCracken $1,911,764
Vikram Jog $1,391,445
Bradley Kreger $1,352,299
Nicholas Khadder $1,257,775
Fiscal 2018
Executive Total
Stephen Christopher Linthwaite $2,585,213
Vikram Jog $1,125,539
Nicholas Khadder $1,091,461
Bradley Kreger $995,197
Fiscal 2017
Executive Total
Stephen Christopher Linthwaite $2,019,870
Vikram Jog $974,126
Nicholas Khadder $925,210

Executive changes

Person Change Filed
Eli Casdin Already on the board
Since at least 2022: re-election or new board role
2026-06-18
Thomas Carey Already on the board
Since at least 2024: re-election or new board role
2026-06-18
Michael Egholm, Ph.D. Appointed 2026-06-18
Spencer Smith Appointed 2026-06-08
Dr. Jeff Engelman Appointed 2026-06-08
Dr. Josh Bilenker Appointed 2026-06-08
Frank Witney, Ph.D. Appointed 2025-06-20
Kathy Hibbs Appointed 2025-06-20
Jeremy Davis Terminated 2025-01-10
Alex Kim Appointed 2024-11-07
Alex Kim Appointed 2024-07-31
Jeffrey Black
“Mr. Black’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, and was driven by his desire to accept an opportunity at another public company.”
Resigned 2024-07-31
Fenel M. Eloi Appointed 2024-07-01
Troy Cox Appointed 2024-07-01
Martin Madaus
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-01-05
Carlos Paya
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-01-05
Shane Bowen Appointed 2024-01-05
Adam Taich Appointed 2024-01-05
Troy Cox Appointed 2024-01-05
Tom Carey Appointed 2024-01-05
Tom Carey Appointed 2024-01-05
Kathy Hibbs Appointed 2024-01-05
Martin Madaus, Ph.D.
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-01-05
Laura Clague
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-01-05
Carlos Paya, M.D., Ph.D.
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-01-05

Leadership

Key facts CIK 1162194 CUSIP 34385P108 13F (30d) 121 filings 100 filers Visit website Investor relations